QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells 期刊论文 CANCER MEDICINE, 2019, 卷号: 8, 期号: 15, 页码: 6730-6740 作者:  Lu, Qin;  Zhang, Fang-Lin;  Lu, Da-Yun;  Shao, Zhi-Ming;  Li, Da-Qiang 收藏  |  浏览/下载：21/0  |  提交时间：2020/07/01 BRCA1  breast cancer  deubiquitinase  PARP inhibitor  USP9X   Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity 期刊论文 CANCER RESEARCH, 2019, 卷号: 79, 期号: 13, 页码: 2 作者:  Chen, Hua-Dong;  Chen, Chuan-Huizi;  Wang, Yu-Ting;  Guo, Ne;  Tian, Yu-Nan 收藏  |  浏览/下载：3/0  |  提交时间：2020/07/01 Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials 期刊论文 CANCER SCIENCE, 2019, 卷号: 110, 期号: 3, 页码: 1064-1075 作者:  Wang, Lei;  Yang, Changyong;  Xie, Chengying;  Jiang, Jiahua;  Gao, Mingzhao 收藏  |  浏览/下载：22/0  |  提交时间：2020/07/01 antitumor activity  fluzoparib  pharmacokinetics  poly(ADP-ribose) polymerase  toxicity   Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors 期刊论文 Journal of enzyme inhibition and medicinal chemistry, 2019, 卷号: 34, 页码: 150-162 作者:  Gao Cheng-Zhi[1];  Dong Wei[2];  Cui Zhi-Wen[3];  Yuan Qiong[4];  Hu Xia-Min[5] 收藏  |  浏览/下载：33/0  |  提交时间：2019/04/22 AChE  Alzheimer's Disease  BChE  Olaparib  PARP-1 inhibitor   Pharmacologic Characterization of Fluzoparib, a Novel Poly polymerase Inhibitor Undergoing Clinical Trials. 期刊论文 Cancer science, 2019 作者:  Lei Wang;  Changyong Yang;  Chengying Xie;  Jiahua Jiang;  Mingzhao Gao 收藏  |  浏览/下载：14/0  |  提交时间：2019/12/13 PARP  Antitumor  activity  Fluzoparib  Pharmacokinetics  Toxicity   Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors 期刊论文 JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 卷号: 34, 期号: 1 作者:  Gao, Cheng-Zhi;  Dong, Wei;  Cui, Zhi-Wen;  Yuan, Qiong;  Hu, Xia-Min 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/06 PARP-1 inhibitor  Olaparib  AChE  BChE  Alzheimer's Disease   OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer 期刊论文 2019, 卷号: 30, 期号: 4, 页码: 558-566 作者:  Robson, M. E.;  Tung, N.;  Conte, P.;  Im, S-A;  Senkus, E. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/03 breast cancer  germline BRCA mutation  overall survival  PARP inhibitor  olaparib  tolerability   Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours 期刊论文 2019, 卷号: 83, 期号: 5, 页码: 963-974 作者:  Yuan, Peng;  Shentu, Jianzhong;  Xu, Jianming;  Burke, Wendy;  Hsu, Kate 收藏  |  浏览/下载：11/0  |  提交时间：2020/01/03 Chinese patients  Olaparib  Paclitaxel  PARP inhibitor  Pharmacokinetics  Safety   PI3K alpha inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment 期刊论文 CANCER LETTERS, 2019, 卷号: 459, 页码: 145-155 作者:  Shi, Jia-jie;  Xing, Hui;  Wang, Yu-xiang;  Zhang, Xi;  Zhan, Qi-min 收藏  |  浏览/下载：16/0  |  提交时间：2020/07/01 CYH33  Radiation  Synergism  ESCC  PI3K alpha